title: Regulation of lymphocyte pseudopodia formation by triggering the integrin alpha 4/beta 1.
abstract: Video microscopy and digital imaging were used to quantitatively analyze lymphocyte adhesion and formation of pseudopodia on the extracellular matrix protein fibronectin (FN). A morphology kinetics assay comparing pseudopodial extension values over a 24-h period showed that HPB-ALL T leukemic cells undergo a wave of morphologic change, returning to a round shape after 8 h. Using anti-alpha 4 and anti-alpha 5 mAbs and a panel of cell types that are single or double positive for expression of the alpha 4/beta 1 and alpha 5/beta 1 FN binding integrins, it was determined that cell adhesion to FN was influenced by both beta 1-integrins, whereas alpha 4/beta 1 was found to be the major FN receptor mediating pseudopodia extension. The protein kinase inhibitor staurosporine, the protein kinase C inhibitors calphostin C and chelerythrine, and the protein tyrosine kinase inhibitor herbimycin A blocked pseudopodial extension in HPB-ALL cells. In contrast, two cAMP-dependent protein kinase inhibitors H8 and H89 did not inhibit. Inhibitors of phospholipase A2, lipoxygenases, and cyclooxygenases could block formation of pseudopodia, yet had little or no effect on cell adhesion to FN. The preincubation of cells with arachidonic acid could prevent the inhibition mediated by the reversible phospholipase A2 inhibitor cibacron blue. We conclude that the formation of lymphocyte pseudopodia in response to FN can utilize the adhesive and signaling activities of the alpha 4/beta 1-integrin and the enzymatic activities of protein kinases and phospholipases.
authors.affiliation: Department of Immunology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
authors.forename: M C
authors.initials: MC
authors.lastname: Szabo
authors.forename: T K
authors.initials: TK
authors.lastname: Teague
authors.forename: B W
authors.initials: BW
authors.lastname: McIntyre
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D016718:Arachidonic Acid / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects; D002460:Cell Line; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D007091:Image Processing, Computer-Assisted; D039041:Integrin alpha4beta1; D016023:Integrins / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000378:metabolism; D007700:Kinetics; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008214:Lymphocytes / Q000276:immunology* / Q000502:physiology / Q000648:ultrastructure; D018715:Microscopy, Video; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D054467:Phospholipases A2; D047428:Protein Kinase Inhibitors; D011554:Pseudopodia / Q000276:immunology* / Q000502:physiology / Q000648:ultrastructure; D015398:Signal Transduction
chemical_list: D000911:Antibodies, Monoclonal; D016861:Cyclooxygenase Inhibitors; D005353:Fibronectins; D039041:Integrin alpha4beta1; D016023:Integrins; D016859:Lipoxygenase Inhibitors; D047428:Protein Kinase Inhibitors; D016718:Arachidonic Acid; D010741:Phospholipases A; D054467:Phospholipases A2